General Description
Ethotoin is a hydantoin anticonvulsant chemically related to phenytoin but with lower toxicity and reduced efficacy. It is available in oral tablets and is used primarily as an alternative for the management of generalized tonic-clonic and complex partial seizures. The drug is less potent than phenytoin and has a shorter half-life, requiring more frequent dosing.
Mechanism of Action
Ethotoin stabilizes neuronal membranes by blocking voltage-gated sodium channels, particularly in their inactivated state. This inhibition reduces sustained repetitive firing of action potentials in seizure foci, preventing the spread of abnormal electrical activity. Unlike phenytoin, ethotoin has a more favorable effect on cardiac conduction and produces fewer cerebellar and vestibular side effects, though its precise binding site on the sodium channel may differ subtly.
Application
It is indicated for the control of generalized tonic-clonic seizures and complex partial (temporal lobe) seizures, typically as an adjunct when other agents have failed or caused intolerable side effects. It is not considered a first-line therapy due to its lower efficacy compared to phenytoin and newer anticonvulsants. Common adverse effects include gastrointestinal upset, drowsiness, and nystagmus. Gingival hyperplasia and hirsutism, seen with phenytoin, are less common with ethotoin.